Rapamycin: Friend, foe, or misunderstood?
Article first published online: 30 DEC 2003
Copyright © 2003 American Association for the Study of Liver Diseases
Volume 9, Issue 5, pages 469–472, May 2003
How to Cite
Fung, J. and Marcos, A. (2003), Rapamycin: Friend, foe, or misunderstood?. Liver Transpl, 9: 469–472. doi: 10.1053/jlts.2003.50101
- Issue published online: 30 DEC 2003
- Article first published online: 30 DEC 2003
- 4Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999; 67:1031–1042., , , , , , et al.
- 5Transplantation (in press), , , , . Airway anastomotic dehiscence associated with the use of sirolimus immediately after lung transplantation.
- 10MacDonald AS for the RAPAMUNE Global Study Group. A worldwide, phase III, randomized, controlled, safety and efficacy study of sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001; 71:271–280.
- 12the Rapamune Liver Transplant Study Group. Sirolimus immunotherapy results in reduced rates of acute rejection in de novo orthotopic liver transplant recipients. Am J Transplant 2002; 2:464., , , and
- 13Wiesner R for the Rapamune Liver Transplant Study Group. The safety and efficacy of sirolimus and low-dose tacrolimus versus tacrolimus in de novo orthotopic liver transplant recipients. Results from a pilot study [Abstract]. Hepatology 2002; 36:208A.
- 14Physician Desk Reference 2003: Rapamune Oral Solution—Sirolimus—Wyeth Pharmaceuticals. Physician Desk Reference 2003 (ed 57). Montvale, NJ: Thomson Healthcare, 2003: 3469–3474.